IMBRUVICA (Ibrutinib Capsules)
Description of Imbruvica 140 mg (Ibrutinib Capsules)
A Bruton’s Tyrosine Kinase Inhibitor (BTK)
Its use and Indications
Imbruvica (Ibrutinib) Capsules is indicated in the following:
*Mantle Cell Lymphoma
- Treatment of patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy
*Accelerated approval was granted for this indication based on overall response rate
Chronic Lymphocytic Leukemia
- Treatment of patients with Chronic Lymphocytic Leukemia (CLL) who have received at least one prior therapy (see clinical studies)
- Treatment of patients with Chronic Lymphocytic Leukemia (CLL) with 17p deletion (see clinical studies)
- Imbruvica is indicated for the patients with Waldenstrom’s Macroglobulinemia (WM)
- (see clinical studies)
For treatment related information, please consult your treating Physician.
Imbruvica 140 mg Capsules in a bottle of 90 and 120 capsules
Storage and handling
Store at 20°- 25° C, excursions permitted to 15° to 30° C.
How do we source the Drug?
Super Specialities Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is also essential.
Company that Manufactures/ Markets:
M/s Janssen Biotec, Inc
Mob No: +91 7738100125, +91 7738151650
E Mail: email@example.com